Eye Hospital, Wenzhou Medical College, Wenzhou, China.
PLoS One. 2012;7(8):e44855. doi: 10.1371/journal.pone.0044855. Epub 2012 Aug 31.
Leber congenital amaurosis (LCA) is one of the most severe forms of inherited retinal degeneration and can be caused by mutations in at least 15 different genes. To clarify the proteomic differences in LCA eyes, a cohort of retinal degeneration 12 (rd12) mice, an LCA2 model caused by a mutation in the RPE65 gene, were injected subretinally with an AAV vector (scAAV5-smCBA-hRPE65) in one eye, while the contralateral eye served as a control. Proteomics were compared between untreated rd12 and normal control retinas on P14 and P21, and among treated and untreated rd12 retinas and control retinas on P42. Gene therapy in rd12 mice restored retinal function in treated eyes, which was demonstrated by electroretinography (ERG). Proteomic analysis successfully identified 39 proteins expressed differently among the 3 groups. The expression of 3 proteins involved in regulation of apoptosis and neuroptotection (alpha A crystallin, heat shock protein 70 and peroxiredoxin 6) were investigated further. Immunofluorescence, Western blot and real-time PCR confirmed the quantitative changes in their expression. Furthermore, cell culture studies suggested that peroxiredoxin 6 could act in an antioxidant role in rd12 mice. Our findings support the feasibility of gene therapy in LCA2 patients and support a role for alpha A crystallin, heat shock protein 70 and peroxiredoxin 6 in the pathogenetic mechanisms involved in LCA2 disease process.
Leber 先天性黑蒙(LCA)是最严重的遗传性视网膜变性形式之一,可由至少 15 种不同基因的突变引起。为了阐明 LCA 眼中的蛋白质组差异,对一组视网膜变性 12 型(rd12)小鼠进行了研究,该模型是由 RPE65 基因突变引起的 LCA2 型。在一只眼的玻璃体内注射 AAV 载体(scAAV5-smCBA-hRPE65),而对侧眼作为对照。在 P14 和 P21 时,将未经处理的 rd12 与正常对照视网膜之间,以及在 P42 时,将治疗组和未治疗组 rd12 视网膜与对照组视网膜之间的蛋白质组进行了比较。在 rd12 小鼠中进行基因治疗可恢复治疗眼的视网膜功能,这通过视网膜电图(ERG)得到证实。蛋白质组分析成功地鉴定出 3 组之间表达不同的 39 种蛋白质。进一步研究了 3 种参与细胞凋亡和神经保护调节的蛋白质(α A 晶体蛋白、热休克蛋白 70 和过氧化物酶 6)的表达情况。免疫荧光、Western blot 和实时 PCR 证实了它们表达的定量变化。此外,细胞培养研究表明,过氧化物酶 6 在 rd12 小鼠中可能发挥抗氧化作用。我们的研究结果支持在 LCA2 患者中进行基因治疗的可行性,并支持α A 晶体蛋白、热休克蛋白 70 和过氧化物酶 6 在 LCA2 疾病过程中的发病机制中发挥作用。